Nonclinical Safety and Translational Assessment — Pharmaron

At Pharmaron, we build each nonclinical safety and translational assessment engagement around context. The right plan depends on what has already been learned, what remains uncertain, which inputs are ready, and how the results will influence the next decision. Our team brings those factors together early so the work has a clear purpose, an agreed path, and deliverables matched to your program.

Our nonclinical safety and translational assessment capabilities

We provide integrated nonclinical services for programs that need to connect exposure, biological activity, and safety findings before clinical development. Its laboratory organization includes safety assessment, DMPK, bioanalysis, and specialized testing capabilities. The service is relevant to teams assembling an evidence package for candidate selection, IND-enabling work, or other preclinical development decisions. An integrated plan should identify the molecule or modality, intended route, known liabilities, regulatory objective, exposure measures, study sequence, and quality requirements. Individual assays and studies must be selected with our scientific and regulatory teams. Discuss the candidate profile and next development milestone with us to determine the appropriate safety, DMPK, and bioanalytical workstreams. This work sits within our Pre-Clinical Research, Toxicology Studies capabilities and is coordinated with the wider program context when the scope requires it.

• In vitro toxicology focused on metabolism-related safety risks
• Testing across small molecules, biologics, cell and gene therapies, ocular products, and medical devices where appropriate

How we shape the scope

A strong scope makes the work easier to execute and easier to evaluate. We document the core question, required inputs, proposed activities, review points, and expected outputs, then connect each element to a program need. Where multiple approaches could be reasonable, we explain the tradeoffs and agree how the choice will be made. That discipline helps protect timelines while giving the technical team room to respond to the evidence.

Working with Pharmaron

We work as an extension of the program team while maintaining clear ownership of actions and decisions. Regular reviews cover completed work, near-term priorities, risks, and information needed from either side. If new evidence changes the best route, we explain the reason, the available alternatives, and the effect on deliverables or timing. The goal is a transparent engagement in which technical detail supports progress instead of obscuring it.

Deliverables built for the next decision

Outputs are planned for the people who will use them next. At kickoff, we agree on the required files, summaries, documentation, and review process rather than assuming a standard package will fit every program. Our final review connects the deliverables back to the original objective and highlights material observations, limitations within the performed scope, and follow-up questions. This makes the handoff more useful for internal review, partner discussions, and subsequent development planning.

Planning your nonclinical safety and translational assessment project with Pharmaron

The best starting point for nonclinical safety and translational assessment is a concise brief covering the program question, current evidence, available inputs, constraints, expected outputs, and desired timeline. We use that brief to prepare a practical scope and identify any questions that should be resolved first. The proposal then gives both teams a shared basis for evaluating approach, effort, milestones, deliverables, and next steps.